Gonococcal resistance to zoliflodacin could emerge via transformation from commensal Neisseria species. An in-vitro transformation study

Abstract One of the most promising new treatments for gonorrhoea currently in phase 3 clinical trials is zoliflodacin. Studies have found very little resistance to zoliflodacin in currently circulating N. gonorrhoeae strains, and in-vitro experiments demonstrated that it is difficult to induce resis...

Full description

Bibliographic Details
Main Authors: Saïd Abdellati, Jolein Gyonne Elise Laumen, Tessa de Block, Irith De Baetselier, Dorien Van Den Bossche, Christophe Van Dijck, Sheeba Santhini Manoharan-Basil, Chris Kenyon
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-49943-z